Authors/Task Force members, Elliott, P.M., Anastasakis, A., Borger,
M.A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A.A., Lafont,
A., Limongelli, G., et al. (2014). 2014 ESC Guidelines on diagnosis
and management of hypertrophic cardiomyopathy: the Task Force
for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 35,
2733–2779. https://doi.org/10.1093/eurheartj/ehu284.
Cohn, R., Thakar, K., Lowe, A., Ladha, F.A., Pettinato, A.M.,
Romano, R., Meredith, E., Chen, Y.S., Atamanuk, K., Huey, B.D.,
and Hinson, J.T. (2019). A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations. Stem Cell
Rep. 12, 71–83. https://doi.org/10.1016/j.stemcr.2018.11.015.
Fujiwara, Y., Deguchi, K., Miki, K., Nishimoto, T., and Yoshida, Y.
(2021). A Method for Contraction Force Measurement of hiPSCDerived Engineered Cardiac Tissues. Methods Mol. Biol. 2320,
171–180. https://doi.org/10.1007/978-1-0716-1484-6_17.
Funakoshi, S., Fernandes, I., Mastikhina, O., Wilkinson, D., Tran,
T., Dhahri, W., Mazine, A., Yang, D., Burnett, B., Lee, J., et al.
(2021). Generation of mature compact ventricular cardiomyocytes
from human pluripotent stem cells. Nat. Commun. 12, 3155.
https://doi.org/10.1038/s41467-021-23329-z.
Helms, A.S., Thompson, A.D., Glazier, A.A., Hafeez, N., Kabani, S.,
Rodriguez, J., Yob, J.M., Woolcock, H., Mazzarotto, F., Lakdawala,
N.K., et al. (2020). Spatial and Functional Distribution of
MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients
With Hypertrophic Cardiomyopathy. Circ. Genom. Precis. Med.
13, 396–405. https://doi.org/10.1161/CIRCGEN.120.002929.
Ho, C.Y., Charron, P., Richard, P., Girolami, F., Van SpaendonckZwarts, K.Y., and Pinto, Y. (2015). Genetic advances in sarcomeric
cardiomyopathies: state of the art. Cardiovasc. Res. 105, 397–408.
https://doi.org/10.1093/cvr/cvv025.
Karbassi, E., Fenix, A., Marchiano, S., Muraoka, N., Nakamura, K.,
Yang, X., and Murry, C.E. (2020). Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine.
Nat. Rev. Cardiol. 17, 341–359. https://doi.org/10.1038/s41569019-0331-x.
Knight, W.E., Cao, Y., Lin, Y.H., Chi, C., Bai, B., Sparagna, G.C.,
Zhao, Y., Du, Y., Londono, P., Reisz, J.A., et al. (2021). Maturation
of Pluripotent Stem Cell-Derived Cardiomyocytes Enables
Modeling of Human Hypertrophic Cardiomyopathy. Stem Cell
Rep. 16, 519–533. https://doi.org/10.1016/j.stemcr.2021.01.018.
Lan, F., Lee, A.S., Liang, P., Sanchez-Freire, V., Nguyen, P.K., Wang,
L., Han, L., Yen, M., Wang, Y., Sun, N., et al. (2013). Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent
stem cells. Cell Stem Cell 12, 101–113. https://doi.org/10.1016/j.
stem.2012.10.010.
Leonard, A., Bertero, A., Powers, J.D., Beussman, K.M., Bhandari, S.,
Regnier, M., Murry, C.E., and Sniadecki, N.J. (2018). Afterload promotes maturation of human induced pluripotent stem cell derived
cardiomyocytes in engineered heart tissues. J. Mol. Cell. Cardiol.
118, 147–158. https://doi.org/10.1016/j.yjmcc.2018.03.016.
Lompre, A.M., Mercadier, J.J., Wisnewsky, C., Bouveret, P., Pantaloni, C., D’Albis, A., and Schwartz, K. (1981). Species- and agedependent changes in the relative amounts of cardiac myosin isoenzymes in mammals. Dev. Biol. 84, 286–290. https://doi.org/10.
1016/0012-1606(81)90396-1.
Ma, Z., Huebsch, N., Koo, S., Mandegar, M.A., Siemons, B., Boggess,
S., Conklin, B.R., Grigoropoulos, C.P., and Healy, K.E. (2018). Contractile deficits in engineered cardiac microtissues as a result of
MYBPC3 deficiency and mechanical overload. Nat. Biomed. Eng.
2, 955–967. https://doi.org/10.1038/s41551-018-0280-4.
Maron, B.J., Gardin, J.M., Flack, J.M., Gidding, S.S., Kurosaki, T.T.,
and Bild, D.E. (1995). Prevalence of hypertrophic cardiomyopathy
in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk
Development in (Young) Adults. Circulation 92, 785–789.
https://doi.org/10.1161/01.cir.92.4.785.
Marston, S., Copeland, O., Jacques, A., Livesey, K., Tsang, V.,
McKenna, W.J., Jalilzadeh, S., Carballo, S., Redwood, C., and Watkins, H. (2009). Evidence from human myectomy samples that
MYBPC3 mutations cause hypertrophic cardiomyopathy through
haploinsufficiency. Circ. Res. 105, 219–222. https://doi.org/10.
1161/CIRCRESAHA.109.202440.
Miki, K., Deguchi, K., Nakanishi-Koakutsu, M., Lucena-Cacace, A.,
Kondo, S., Fujiwara, Y., Hatani, T., Sasaki, M., Naka, Y., Okubo, C.,
et al. (2021). ERRgamma enhances cardiac maturation with
T-tubule formation in human iPSC-derived cardiomyocytes. Nat.
Commun. 12, 3596. https://doi.org/10.1038/s41467-021-23816-3.
Stem Cell Reports j Vol. 18 j 2108–2122 j November 14, 2023 2121
Milani-Nejad, N., and Janssen, P.M.L. (2014). Small and large animal models in cardiac contraction research: advantages and disadvantages. Pharmacol. Ther. 141, 235–249. https://doi.org/10.
1016/j.pharmthera.2013.10.007.
Miron, A., Lafreniere-Roula, M., Steve Fan, C.P., Armstrong, K.R.,
Dragulescu, A., Papaz, T., Manlhiot, C., Kaufman, B., Butts, R.J.,
Gardin, L., et al. (2020). A Validated Model for Sudden Cardiac
Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy.
Circulation 142, 217–229. https://doi.org/10.1161/CIRCULATIONAHA.120.047235.
Mosqueira, D., Mannhardt, I., Bhagwan, J.R., Lis-Slimak, K., Katili,
P., Scott, E., Hassan, M., Prondzynski, M., Harmer, S.C., Tinker, A.,
et al. (2018). CRISPR/Cas9 editing in human pluripotent stem cellcardiomyocytes highlights arrhythmias, hypocontractility, and
energy depletion as potential therapeutic targets for hypertrophic
cardiomyopathy. Eur. Heart J. 39, 3879–3892. https://doi.org/10.
1093/eurheartj/ehy249.
Mosqueira, D., Smith, J.G.W., Bhagwan, J.R., and Denning, C.
(2019). Modeling Hypertrophic Cardiomyopathy: Mechanistic Insights and Pharmacological Intervention. Trends Mol. Med. 25,
775–790. https://doi.org/10.1016/j.molmed.2019.06.005.
Bhavsar, P.K., Dhoot, G.K., Cumming, D.V., Butler-Browne, G.S.,
Yacoub, M.H., and Barton, P.J. (1991). Developmental expression
of troponin I isoforms in fetal human heart. FEBS Lett. 292, 5–8.
https://doi.org/10.1016/0014-5793(91)80820-s.
Piquereau, J., and Ventura-Clapier, R. (2018). Maturation of Cardiac Energy Metabolism During Perinatal Development. Front.
Physiol. 9, 959. https://doi.org/10.3389/fphys.2018.00959.
Ronaldson-Bouchard, K., Ma, S.P., Yeager, K., Chen, T., Song, L., Sirabella, D., Morikawa, K., Teles, D., Yazawa, M., and Vunjak-Novakovic, G. (2018). Advanced maturation of human cardiac tissue
grown from pluripotent stem cells. Nature 556, 239–243. https://
doi.org/10.1038/s41586-018-0016-3.
2122 Stem Cell Reports j Vol. 18 j 2108–2122 j November 14, 2023
Ruan, J.L., Tulloch, N.L., Razumova, M.V., Saiget, M., Muskheli, V.,
Pabon, L., Reinecke, H., Regnier, M., and Murry, C.E. (2016). Mechanical Stress Conditioning and Electrical Stimulation Promote
Contractility and Force Maturation of Induced Pluripotent Stem
Cell-Derived Human Cardiac Tissue. Circulation 134, 1557–1567.
https://doi.org/10.1161/CIRCULATIONAHA.114.014998.
Schuldt, M., Pei, J., Harakalova, M., Dorsch, L.M., Schlossarek, S.,
Mokry, M., Knol, J.C., Pham, T.V., Schelfhorst, T., Piersma, S.R.,
et al. (2021). Proteomic and Functional Studies Reveal Detyrosinated
Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy. Circ. Heart Fail. 14, e007022. https://doi.
org/10.1161/CIRCHEARTFAILURE.120.007022.
Seeger, T., Shrestha, R., Lam, C.K., Chen, C., McKeithan, W.L., Lau,
E., Wnorowski, A., McMullen, G., Greenhaw, M., Lee, J., et al.
(2019). A Premature Termination Codon Mutation in MYBPC3
Causes Hypertrophic Cardiomyopathy via Chronic Activation of
Nonsense-Mediated Decay. Circulation 139, 799–811. https://
doi.org/10.1161/CIRCULATIONAHA.118.034624.
Somura, F., Izawa, H., Iwase, M., Takeichi, Y., Ishiki, R., Nishizawa,
T., Noda, A., Nagata, K., Yamada, Y., and Yokota, M. (2001).
Reduced myocardial sarcoplasmic reticulum Ca(2+)-ATPase
mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation 104, 658–
663. https://doi.org/10.1161/hc3101.093869.
Van Driest, S.L., Ackerman, M.J., Ommen, S.R., Shakur, R., Will,
M.L., Nishimura, R.A., Tajik, A.J., and Gersh, B.J. (2002). Prevalence
and severity of "benign" mutations in the beta-myosin heavy
chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 106, 3085–3090. https://doi.
org/10.1161/01.cir.0000042675.59901.14.
Yu, G., Wang, L.G., Yan, G.R., and He, Q.Y. (2015). DOSE: an R/Bioconductor package for disease ontology semantic and enrichment
analysis. Bioinformatics 31, 608–609. https://doi.org/10.1093/bioinformatics/btu684.
...
論文の公開元へ
